Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
This study has been completed.
Study NCT00364546   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: August 11, 2006   Last Updated: September 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoarthritis
Pain Intensity Assessment
Arthralgia
Sciatica
Low Back Pain
Additional conditions recognized in this trial
Back Pain
More general conditions related to this trial
Arthritis
Joint Diseases
Mononeuropathies
Musculoskeletal Diseases
Nervous System Diseases
Neuralgia
Neurologic Manifestations
Neuromuscular Diseases
Pain
Peripheral Nervous System Diseases
Rheumatic Diseases
Sciatic Neuropathy
Signs and Symptoms
Interventions listed in this trial
CG 5503;tapentadol
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Grünenthal GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services